COFG Advisors LLC Buys Shares of 746 Eli Lilly and Company $LLY

COFG Advisors LLC bought a new stake in Eli Lilly and Company (NYSE:LLY) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 746 shares of the company’s stock, valued at approximately $802,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth about $12,976,634,000. Capital Research Global Investors boosted its position in shares of Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after buying an additional 4,332,008 shares during the period. Vanguard Group Inc. boosted its position in shares of Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after buying an additional 1,006,885 shares during the period. Amundi boosted its position in shares of Eli Lilly and Company by 27.1% during the third quarter. Amundi now owns 4,525,902 shares of the company’s stock worth $3,823,977,000 after buying an additional 964,675 shares during the period. Finally, Jennison Associates LLC boosted its position in shares of Eli Lilly and Company by 22.3% during the fourth quarter. Jennison Associates LLC now owns 5,133,676 shares of the company’s stock worth $5,517,059,000 after buying an additional 937,204 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Wells Fargo & Company upped their price objective on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. CICC Research raised their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research note on Wednesday, February 11th. Cantor Fitzgerald raised their price target on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the company an “overweight” rating in a research note on Friday, May 1st. Truist Financial restated a “buy” rating on shares of Eli Lilly and Company in a research note on Monday, February 23rd. Finally, Bank of America raised their price target on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a “buy” rating in a research note on Tuesday, May 26th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,227.00.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,079.96 on Tuesday. The firm has a market cap of $1.02 trillion, a P/E ratio of 38.36, a price-to-earnings-growth ratio of 1.21 and a beta of 0.53. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,149.10. The business’s 50 day moving average is $959.18 and its 200-day moving average is $1,010.74.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same quarter last year, the company earned $3.34 EPS. The company’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported strong Phase 3 data for Retevmo (selpercatinib), showing an 83% reduction in the risk of disease recurrence or death in early-stage RET fusion-positive lung cancer, a result that could support a broader label and future revenue growth. Article Title
• Positive Sentiment: The company also signed new licensing and collaboration deals with Hanmi and Haisco, extending its innovation pipeline and signaling continued deal-making momentum in Asia. Article Title
• Positive Sentiment: Camurus said Lilly exercised an option in their cardiometabolic drug collaboration, extending another pipeline partnership and adding to investor confidence in Lilly’s long-term growth strategy. Article Title
• Positive Sentiment: Market commentary remained bullish after CEO David Ricks’ remarks about Lilly’s hot product lineup, while social sentiment and analyst coverage continued to highlight the company as one of the market’s leading growth names. Article Title
• Neutral Sentiment: Some articles framed Lilly as one of the top stocks to watch, but these pieces were mostly commentary rather than new company-specific catalysts. Article Title
• Negative Sentiment: Despite the positive news, LLY has been trading lower recently, and some market attention appears to reflect profit-taking after a strong run and valuation concerns rather than a deterioration in fundamentals. Article Title
• Negative Sentiment: Competitive pressure in the GLP-1 market remains a risk, as Novo Nordisk’s oral Wegovy pill is still outperforming Lilly’s rival tablet, even though growth is slowing. Article Title

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.